KR20230070652A - Composition for preventing and improving muscular atrophy or sarcopenia comprising bean leaf extract and yeast as active ingredients - Google Patents

Abstract

The present invention relates to a composition for preventing and improving muscular atrophy or sarcopenia comprising bean leaf extract and yeast as active ingredients. According to the present invention, provided is a composition based on natural products including yeast as an active ingredient along with bean leaf extract. The composition can prevent and improve muscular atrophy or sarcopenia and exhibit a muscle strengthening effect.

Description

Composition for preventing and improving muscular dystrophy or sarcopenia containing soybean leaf extract and yeast as active ingredients

The present invention relates to a composition for preventing and improving muscular dystrophy or sarcopenia, comprising a soybean leaf extract and yeast as active ingredients. More specifically, it is to provide a natural product-based composition including yeast as an active ingredient along with a soybean leaf extract, to prevent and improve muscular dystrophy or sarcopenia and to exhibit a muscle strengthening effect through the composition. In particular, while providing various formulations as food and health functional food, it is intended to use ingredients based on natural materials so that there is no problem of side effects even when taken for a long time to prevent and improve sarcopenia or strengthen muscle strength.

Sarcopenia caused by degeneration of spinal nerves, motor nerves, or skeletal muscle fibers is one of the representative intractable diseases whose causes have not yet been identified. According to studies so far, skeletal muscle contraction does not progress because motor nerves that induce skeletal muscle contraction are degenerated, or the expression of proteins involved in muscle contraction is reduced in skeletal muscle, or the protein is modified to normal contraction of skeletal muscle. This does not progress, and in the long term, it is known that the motor nerve or skeletal muscle is transformed into fibrous tissue. Since the fundamental cause of sarcopenia has not yet been identified, and a method for preventing or recovering the degeneration of motor neurons or skeletal muscles has not been developed, it is currently difficult to develop a method for slowing the progression of sarcopenia. Research is actively under way.

On the other hand, amyotrophic disease is a disease in which the muscles of the limbs atrophy, and amyotrophic lateral sclerosis and spinal progressive muscular atrophy are representative, and it is known as a disease caused by progressive degeneration of motor nerve fibers and cells in the spinal cord. Specifically, the spinal muscular atrophy is a genetic disorder caused by degeneration of motor neurons in the spinal cord and is known as one of the neuromuscular diseases. In addition, amyotrophic lateral sclerosis is characterized by intractable and irreversible neurodegenerative changes caused by the death of upper motor neurons and lower motor neurons of the cerebrum and spinal cord, and it is known that lack of nerve growth factors and neuroinflammation are the main causes.

The above-mentioned sarcopenia or muscular dystrophy has a strong tendency to accompany or accelerate with aging. Conventionally, there has been a tendency to recognize the above diseases as one of the natural physiological phenomena caused by aging, but currently, efforts are being actively made to recognize them as diseases and prevent sarcopenia or muscular atrophy or improve it by slowing its progress.

Looking more specifically, a representative physiological change according to aging is a decrease in muscle mass and strength. It is known that muscle mass loss occurs after the age of 40 and decreases by about 8% per 10 years until the age of 70.

Skeletal muscle is the largest organ in the human body, accounting for 40-50% of the total body weight, and plays an important role in various metabolic functions in the body, including energy homeostasis and heat generation. A person's muscle decreases by more than 1% every year from the age of 40, and at the age of 80, 50% of the maximum muscle mass decreases, and muscle loss in old age is recognized as the most important factor in deteriorating overall body function. As aging progresses, it is recognized that the body shape changes, such as muscle and fat content and skeletal distortion. If insulin secretion is abnormal, energy cannot be properly supplied to the cells, which can cause muscle development disorders, and sarcopenia increases in diabetic patients than in the general population. In addition, muscle loss causes arthritis, back pain, and chronic pain to further increase, and symptoms of urinary incontinence caused by abdominal obesity can be aggravated, and injuries caused by fractures can increase depression in old age and lead to death. Sarcopenia is a major cause of deteriorating quality of life in association with various diseases. Sarcopenia is known to be closely related to geriatric chronic diseases such as osteoporosis, insulin resistance, and arthritis, and the decrease in physical activity due to aging can be suppressed through the prevention or improvement of sarcopenia.

In this regard, the concept of sarcopenia began when Irwin Rosenberg introduced the term 'sarcopenia' in 1989, which is a compound word of "sarco" meaning muscle and "penia" meaning reduced when looking at its origin in Greek. . Sarcopenia refers to a decrease in muscle strength due to a decrease in muscle mass associated with aging. Here, “muscle” means skeletal muscle and has nothing to do with smooth muscle. In other words, sarcopenia refers to a loss of skeletal muscle mass mainly distributed in the limbs, and it is a marked muscle loss condition that occurs in the late stage of malignant tumors, such as cachexia, and muscle wasting due to acute diseases such as influenza. wasting) or disease of the muscle itself (primary muscle disease).

Sarcopenia not only increases the risk of death due to a decrease in various bodily functions and disabilities by causing a direct decrease in muscle strength, but also increases the risk of death due to a decrease in metabolism and a decrease in immunity, such as high blood pressure, diabetes, arthritis, obesity, and cancer. It may also contribute to an increase in the prevalence of the disease.

Myostatin (MSTN) is a polypeptide growth factor belonging to the superfamily of TGF-β. TGFβ has a large amount of isoforms, which are known to be involved in cell proliferation, apoptosis, differentiation, and bone formation and maintenance (Massague & Chen, 2000). Among them, myostatin belongs to growth differentiation factor (GDF) No. 8, is involved in tissue growth and development, and acts by activating the Smad signal transduction system. In addition, it has been reported to affect bone formation and regeneration by suppressing the cell cycle and proliferation of progenitor cells by the p21 gene. Myostatin is mainly produced in skeletal muscle cells and causes muscle loss and muscle strength reduction in an autocrine manner. It suppresses the expression of IGF-1 or Follistatin, which are involved in muscle hypertrophy, to produce protein synthesis and cell proliferation in myoblasts. is known to inhibit That is, myostatin is a protein that regulates muscle growth and belongs to the transforming growth factor-β (TGF-β) family and is also known as growth and differentiation factor-8 (GDF-8). Begian blue is a MSTN mutant in nature. As 11 bases of the 3rd exon are missing, MSTN protein does not function normally, showing a phenotype with 2 to 3 times more muscle mass than normal cows.

On the other hand, there are three major treatment methods for sarcopenia. The first is exercise. It has been reported that exercise increases the protein synthesis ability of skeletal muscle in the short term and increases muscle strength or mobility in the elderly. However, it is not suitable for long-term treatment. Second, testosterone or anabolic steroids can be used as drug treatment, but this induces masculinization in women and causes side effects such as prostate symptoms in men. Other approved prescriptions include dehydroepiandrosterone (DHEA) and growth hormone, and studies have reported that they can be used as treatments at sites containing SARMs (Selective Androgen Receptor Modulators). In addition, although diet is known as a treatment, nutritional assessments indicate malnutrition, and modern eating habits are inadequate to maintain adequate total body mass.

Muscular atrophy is caused by various causes such as absence of mechanical stimulation, starvation, and cancer. Muscular atrophy can be defined as a loss of muscle tissue caused by not using the muscle or a disease of the muscle itself or damage to the nerves that control the muscle. In general, there are cases in which severe muscle strength loss occurs due to not using muscles, which gradually progresses to muscle atrophy. Sometimes there are signs of deterioration. Muscular atrophy due to the disease of the muscle itself includes myasthenia gravis, muscular dystrophy: progressive muscular dystrophy, myotonic muscular dystrophy, Duchenne type, Becker type, belt type, facial scapular deformity, and inflammation that occurs in the muscle itself. Muscular atrophy due to damage to nerves that control muscles is spinal muscular amyotrophy: Beradnich-Hoffmann type, Kugelberg-Wellander disease, amyotrophic lateral sclerosis (ALS): Lou Gehrig Disease, spinobular muscular atrophy: Kennedy disease, etc. For example, even if exercise or other countermeasures are continuously applied, muscle degeneration inevitably proceeds as in space flight or handicap conditions. Therefore, research on other countermeasures that can overcome the obstacle condition, either an alternative to mechanical stimulation or an addition to mechanical stimulation, is required. A suitable approach to such a countermeasure is to use functional biomaterials derived from natural products that can help maintain muscle mass even under conditions inducing atrophy of muscle fiber proteins.

KR 10-2020-0123009 A KR 10-2019-0120905 A

An object of the present invention is to prevent and improve muscular dystrophy by using a composition containing soybean leaf extract and yeast as active ingredients.

An object of the present invention is to prevent and improve sarcopenia by using a composition containing soybean leaf extract and yeast as active ingredients, and to exhibit a muscle strengthening effect.

An object of the present invention is to provide a composition based on natural products that does not cause side effects caused by long-term use, thereby exhibiting preventive and ameliorative effects on muscular dystrophy or sarcopenia through long-term administration or use.

Another object of the present invention is to provide a food or health functional food containing a composition for preventing and improving muscular dystrophy or sarcopenia with soybean leaf extract and yeast as active ingredients. In particular, while being composed of various formulations, it is intended to exhibit a preventive or ameliorative effect on muscular dystrophy or sarcopenia without problems of side effects while taking it for a long time.

In order to achieve the above object, the composition for preventing or improving sarcopenia according to an embodiment of the present invention may include brewer's yeast powder.

The composition for preventing or improving sarcopenia may further include a soybean leaf extract.

The composition for preventing or improving sarcopenia is peppermint extract, apple mint extract, sage extract, lavender extract, bay extract, thyme extract, oregano extract, borage extract, chamomile extract, lemon balm extract, basil extract, rosemary extract, chrysanthemum extract And it may be one containing any one selected from the group consisting of mixtures thereof.

The composition for preventing or improving sarcopenia may have anti-myostatin activity.

In the composition for preventing or improving sarcopenia, the extract may be extracted using an extraction solvent selected from the group consisting of water, alcohol having 1 to 6 carbon atoms, and mixtures thereof.

In the composition for preventing or improving sarcopenia, the sarcopenia may include muscular dystrophy, myasthenia gravis, muscular dystrophy, myasthenia gravis, hypotonia, muscle weakness, muscular dystrophy, amyotrophic lateral sclerosis or myasthenia gravis.

That is, the composition may be a composition for preventing or improving muscular dystrophy. Sarcopenia, as referred to throughout this specification, includes muscular dystrophy.

Food according to another embodiment of the present invention may contain the composition for preventing or improving sarcopenia.

A health functional food according to another embodiment of the present invention may include the composition for preventing or improving sarcopenia.

Method for preparing a composition for preventing or improving sarcopenia according to another embodiment of the present invention includes peppermint extract, apple mint extract, sage extract, lavender extract, bay extract, thyme extract, oregano extract, borage extract, chamomile extract, A drying step of drying a plant selected from the group consisting of lemon balm extract, basil extract, bean leaf extract, rosemary extract, chrysanthemum extract, and mixtures thereof; Powdering step of pulverizing the dried plants according to the drying step; A plant extract preparation step of preparing an extract by adding an extraction solvent selected from the group consisting of water, alcohol having 1 to 6 carbon atoms, and a mixture thereof to the plant subjected to the powdering step; and a brewer's yeast mixing step of mixing brewer's yeast with the plant extract.

Hereinafter, the present invention will be described in more detail.

A composition for preventing or improving sarcopenia according to an embodiment of the present invention may include brewer's yeast powder.

The brewer's yeast is used in the manufacture of brewers' yeast, alcoholic beverages and bread. Brewer's yeast is one of the yeasts necessary for making beer. It is non-fermentable, non-fermentable, contains about 45% protein, and has high vitamin B group and phosphorus content. In addition, the strain produces high-concentration ethanol and has characteristics that can withstand high-concentration ethanol environments. Brewer's yeast contains a large amount of protein, nucleic acid components, carbohydrates, minerals, and vitamins.

As the brewer's yeast, yeast obtained during fermentation of beer may be used. The brewer's yeast is saccharomyces cerevisiae, saccharomyces carlsbergenesis and saccharomyces bayanus (saccharomyces bayanus) at least one yeast of the saccharomyces (saccharomyces) can include

As described later, as a result of evaluation according to an animal-induced sarcopenia model, it can be confirmed that the use of the brewer's yeast can exhibit a preventive or ameliorative effect on sarcopenia. Particularly preferably, the brewer's yeast may include Saccharomyces cerevisiae and Saccharomyces carlsbergenesis, but is not limited thereto. In the case of the above range, the effect of preventing and improving sarcopenia may be excellent.

The composition for preventing or improving sarcopenia may further include a soybean leaf extract. When the soybean leaf extract is additionally mixed, the synergistic effect due to the interaction slows down muscle loss, and the activity of preventing and improving sarcopenia can be higher. That is, when the soybean leaf extract and the brewer's yeast are used in combination, the synergistic effect of the interaction promotes the differentiation of muscle cells and greatly increases the anti-myostatin activity, so it can exhibit a very good effect of preventing or improving sarcopenia. .

The composition for preventing or improving sarcopenia is peppermint extract, apple mint extract, sage extract, lavender extract, bay extract, thyme extract, oregano extract, borage extract, chamomile extract, lemon balm extract, basil extract, rosemary extract, chrysanthemum extract And it may be one containing any one selected from the group consisting of mixtures thereof.

As a synergistic effect due to the interaction of the extract with the brewer's yeast by mixing, the preventive and alleviating activity for sarcopenia can be greatly improved. Accordingly, a better effect can be produced with a smaller content. In particular, it may have an advantage in that there is no problem such as cytotoxicity due to long-term administration.

Preferably, the composition includes brewer's yeast, and may include 180 to 420 parts by weight of soybean leaf extract based on 100 parts by weight of the brewer's yeast. In the case of the above range, the effect of preventing or improving sarcopenia can be greatly increased due to the interaction of each active ingredient.

More preferably, the composition includes brewer's yeast, and may include 180 to 420 parts by weight of soybean leaf extract and 50 to 200 parts by weight of rosemary extract based on 100 parts by weight of the brewer's yeast. In the case of the above-specified composition range, the synergistic activity due to the interaction between brewer's yeast and active ingredients mixed with each extract is greatly increased, and muscle improvement and muscle reduction inhibition including anti-myostatin activity It is very effective in preventing and improving saponification.

More preferably, the composition includes brewer's yeast, and 180 to 420 parts by weight of soybean leaf extract based on 100 parts by weight of the brewer's yeast; 50 to 200 parts by weight of rosemary extract; It may include 20 to 50 parts by weight of thistle extract and 20 to 50 parts by weight of bok choy extract. In the case of the above range, an excellent effect can be achieved with additional synergistic activity. Accordingly, it is possible to achieve excellent preventive and improving effects with a smaller content, and has an advantage that there is no problem of side effects due to long-term administration.

The composition for preventing or improving sarcopenia may have anti-myostatin activity.

In the composition for preventing or improving sarcopenia, the extract may be extracted using an extraction solvent selected from the group consisting of water, alcohol having 1 to 6 carbon atoms, and mixtures thereof.

In the composition for preventing or improving sarcopenia, the sarcopenia may include muscular dystrophy, myasthenia gravis, muscular dystrophy, myasthenia gravis, hypotonia, muscle weakness, muscular dystrophy, amyotrophic lateral sclerosis or myasthenia gravis.

Food according to another embodiment of the present invention may contain the composition for preventing or improving sarcopenia.

Formulations for singi foods include, for example, various foods, beverages, gum, candy, tea, vitamin complexes, functional foods, and the like. In addition, in the present invention, the food includes special nutritional foods (eg, formula milk, infant/young child food, etc.), processed meat products, fish meat products, tofu, jelly, noodles (eg, ramen, noodles, etc.), health supplements, seasoning foods ( Example: soy sauce, soybean paste, gochujang, mixed paste, etc.), sauces, confectionery (eg, snacks), dairy products (eg, fermented milk, cheese, etc.), other processed foods, kimchi, pickled foods (various types of kimchi, pickles, etc.), drinks ( Examples: Fruit drinks, vegetable drinks, soymilk, fermented drinks, ice cream, etc.), natural seasonings (eg, ramen soup, etc.), vitamin complexes, alcoholic beverages, alcoholic beverages, and other health supplements. The food, beverage or food additive may be prepared by a conventional manufacturing method.

A health functional food according to another embodiment of the present invention may include the composition for preventing or improving sarcopenia.

The above health functional food is a food group or food composition that has added value so that the function of the corresponding food acts for a specific purpose by using physical, biochemical, or bioengineering methods, etc. It refers to food designed and processed to fully express the regulatory function in the living body. In a narrow sense, it means a food capable of sufficiently expressing the effect of preventing and alleviating sarcopenia or strengthening muscle strength to the living body. The health functional food may include food additives that are acceptable in food science.

When using the health functional food composition of the present invention as a food additive, the health functional food composition may be added as it is or used together with other foods or food ingredients, and may be appropriately used according to conventional methods. Active ingredients can be appropriately used depending on their purpose of use (prevention or improvement). In general, when preparing food or beverage, the health functional food composition of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less, based on the raw material. However, in the case of long-term intake for health purposes, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.

There is no particular limitation on the type of health functional food. The health functional food composition of the present invention can be made into food, particularly functional food. The functional food of the present invention

It includes components commonly added during food preparation, and includes, for example, proteins, carbohydrates, fats, nutrients, and seasonings. For example, when prepared as a drink, natural carbohydrates or flavors may be included as additional ingredients in addition to active ingredients. The natural carbohydrates are monosaccharides (eg, glucose, fructose, etc.), disaccharides (eg, maltose, sucrose, etc.), oligosaccharides, polysaccharides (eg, dextrins, cyclodextrins, etc.) or sugar alcohols (eg, maltose, sucrose, etc.) , xylitol, sorbitol, erythritol, etc.) are preferred. As the flavoring agent, natural flavoring agents (eg, thaumatin, stevia extract, etc.) and synthetic flavoring agents (eg, saccharin, aspartame, etc.) may be used.

In addition to the health functional food composition, various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonic acid It may further contain a carbonation agent used in beverages and the like.

Method for preparing a composition for preventing or improving sarcopenia according to another embodiment of the present invention includes peppermint extract, apple mint extract, sage extract, lavender extract, bay extract, thyme extract, oregano extract, borage extract, chamomile extract, A drying step of drying a plant selected from the group consisting of lemon balm extract, basil extract, rosemary extract, chrysanthemum extract, and mixtures thereof; Powdering step of pulverizing the dried plants according to the drying step; A plant extract preparation step of preparing an extract by adding an extraction solvent selected from the group consisting of water, alcohol having 1 to 6 carbon atoms, and a mixture thereof to the plant subjected to the powdering step; and a brewer's yeast mixing step of mixing brewer's yeast with the plant extract.

According to the present invention, muscular dystrophy can be prevented and improved by using a composition containing soybean leaf extract and yeast as active ingredients.

According to the present invention, by using a composition containing soybean leaf extract and yeast as active ingredients, sarcopenia can be prevented and improved, and muscle strengthening effects can be exhibited.

The present invention provides a composition based on natural products that does not cause side effects due to long-term use, and provides preventive and improving effects on muscular dystrophy or sarcopenia through long-term administration or use.

According to another embodiment of the present invention, it is possible to provide a food or health functional food containing a composition for preventing and improving muscular dystrophy or sarcopenia using soybean leaf extract and yeast as active ingredients. In particular, while being composed of various formulations, it is intended to exhibit a preventive or ameliorative effect on muscular dystrophy or sarcopenia without problems of side effects while taking it for a long time.

Figure 1 relates to the rate of change in body weight of rats according to the composition according to an embodiment of the present invention in an animal model of sarcopenia.
Figure 2 relates to the results of measuring the femoral weight of rats according to the composition according to an embodiment of the present invention in an animal model for sarcopenia.
3 relates to muscle strength evaluation results for rats according to the composition according to an embodiment of the present invention in an animal-induced sarcopenia model.
Figure 4 relates to the MAFbx expression inhibitory activity of the composition according to an embodiment of the present invention.

Hereinafter, embodiments of the present invention will be described in detail so that those skilled in the art can easily implement the present invention. However, the present invention may be embodied in many different forms and is not limited to the embodiments described herein.

[Production Example: Preparation of brewer's yeast and extract]

In order to confirm the preventive and ameliorative activity of the composition according to the present invention for sarcopenia, the following composition was prepared. Brewer's yeast (AM) was purchased and used as a powder product in which Saccharomyces cerevisiae and Saccharomyces carlsbergenesis were mixed.

Also lavender extract (BM); chamomile extract (CM); rosemary extract (DM); soybean leaf extract (EM); Thistle extract (FM) and bok choy extract (GM) were prepared by drying and extracting with hot water, followed by filtering and powdering.

And in order to confirm the synergistic effect by the mixed extract, each extract was mixed with the composition shown in [Table 1] below.

M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 M11 M12 M13 M14 M15 M16 M17 AM 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 BM 100 - - - - - - - - - - - - - - - CM - 100 - - - - - - - - - - - - - - DM - - 100 - - - - - - 10 50 200 300 50 50 50 50 EM - - 100 150 180 300 420 500 300 300 300 300 300 300 300 300 FM - - - - - - - - - - - - - 10 20 50 70 GM - - - - - - - - - - - - - 10 20 50 70

(unit: parts by weight)

[Experimental Example: Activity evaluation for sarcopenia]

1. Production of an animal-induced sarcopenia model

45 3-week-old male rats were supplied from Hyochang Science (Daegu) and orally administered at 10 am every day for 25 days after acclimatization in the breeding room for 2 weeks. The experimental group was divided into 5 animals per group. In the animal model of sarcopenia, Dexamethasone 98% (Alfa Aesar) was intraperitoneally administered twice a week (1mg/100g), and muscle loss was induced by administering four times for two weeks. To confirm the induction of sarcopenia in animals, skin changes and daily body weight were measured, and a grip strength meter was measured every 5 days. Sufficient water and feed were supplied during the experiment. After 25 days of behavioral evaluation (grip strenght), intramuscular administration of 25 ml of alfaxan (Careside, Korea) + 3.4 ml of rumpum (Bayer, Korea) + 11.6 ml of saline each (based on 150 g) anesthesia and extraction of organs for the experiment (femur) Weight was measured. Anti-slow skeletal myosin heavy chain antibody (ASS) and muscle atrophy F-box antibody (MAFbx) western assay were measured for muscle proteins of the thigh.

In addition, control group 1 (con1) was supplied with physiological saline without inducing sarcopenia, and control group 2 (con2) was supplied with physiological saline after inducing sarcopenia. In addition, each example supplied the preparation example, and the control group and each example were supplied with physiological saline or each preparation example at 10 mg / kg (oral inoculation) once a day according to each feed intake time.

2. Rat weight measurement

Changes in body weight were measured at intervals of 0, 5, 10, 15, 20, and 25 days, and changes were observed. It is shown in [Figure 1] below.

Referring to FIG. 1 below, it can be seen that the weight of rats increases when brewer's yeast (AM) according to the present invention is used in an animal model for sarcopenia. On the other hand, in the case of the plant extract alone, it can be seen that the body weight only increases in the animal-induced model of sarcopenia only when EM is used. In addition, it was confirmed that a synergistic effect appeared when AM and EM were mixed and used, and in particular, a significant synergistic effect was confirmed in the case of the mixing range of M6 to M8. Through this, it can be confirmed that the active ingredients included in the AM and EM exhibit synergistic effects through interaction in the case of the above range.

In addition, in order to derive additional synergistic activity, an experiment was conducted to further mix other plant extracts with respect to M7, which was confirmed to have a high synergistic effect. As a result, although not shown in [Figure 1], it was confirmed that the activity of BM and CM decreased when mixed with M7. However, as can be seen in M10 to M13, it was confirmed that a synergistic effect appeared when DM was mixed with M7 in a certain mixing range, and as can be seen in M14 to M17, FM and GM were additionally mixed in a certain range. In one case, it can be confirmed that an additional synergistic effect is observed.

This can be seen as different in activity of sarcopenia-related active ingredients contained in each extract or because each active ingredient interacts in the mixing range to exhibit a better synergistic effect.

3. Measurement of inguinocrural weight

The inguinocrural weight of the 25th day RAT was measured and shown in [Figure 2] below. Referring to [Fig. 2] below, statistical significance as in [Fig. 1] can be confirmed. Therefore, referring to [Fig. 1] and [Fig. 2], it can be seen that the weight change according to each embodiment is based on the weight change due to muscle loss or muscle gain.

Through this, it can be confirmed that in the case of the present invention, it shows the preventive or ameliorative activity for sarcopenia.

4. Muscle strength evaluation (Grip strength meter, N)

As an animal exercise performance test method, the muscle strength of the rats on the 25th day was evaluated using a grip strength meter. The results are shown in [Figure 3] below. For objective comparison, each value was corrected based on the average value of each group on day 0 so that values on day 25 could be compared.

Referring to [Figure 3] below, when compared with Con2, it can be seen that the muscle strength improvement effect is the most excellent when AM is applied in the case of a single composition in an animal-induced sarcopenia model, and in the case of natural extracts, EM It can be seen that only when the synergistic effect occurs. In addition, when AM and EM are mixed, a synergistic effect that cannot be observed in the mixing of other mixed compositions was confirmed, and in particular, it can be confirmed that a very good muscle strength recovery effect is obtained by the mixing range of M6 to M8.

Also, M11 and M12. In the case of M15 and M16, it can be seen that an additional synergistic effect that was not confirmed in each single or simple mixture with AM appears. Through this, it can be seen that a more excellent muscle strength improvement effect appears in the case of the above range.

5. MAFbx (muscle atrophy F-box antibody) expression evaluation

MAFbx (muscle atrophy F-box antibody) expression was evaluated as a marker of muscle loss in the myotube cells to which the sarcopenia induction model was applied. Protein expression was measured by western blot, the result of con 1 was fixed as 1, and the results of con2 and each example were compared and evaluated. Each value is evaluated as an index, and the lower the number, the better the effect of preventing and improving muscle loss by suppressing the expression of MAFbx. The results are shown in [Figure 4] below.

Referring to FIG. 4 below, it can be confirmed that AM suppresses the expression of MAFbx more effectively than con1. In addition, it can be seen that the mixed composition of AM and EM inhibits the expression of MAFbx more effectively as a synergistic effect that cannot be confirmed in other mixed compositions. In particular, in the case of M6 to M8, it can be seen that the inhibitory activity is very excellent.

Also M11 and M12. In the case of M15 and M16, it can be confirmed that an additional synergistic effect appears.

Therefore, it can be confirmed that the composition provided in the present invention can prevent and improve sarcopenia. In particular, when using a range in which a synergistic effect is exhibited by a mixed composition, an excellent sarcopenia prevention or improvement effect can be enjoyed with a smaller content. Therefore, it is possible to prevent or improve sarcopenia by long-term administration or use without side effects such as cytotoxicity.

On the other hand, the composition can be used for the purpose of preventing or improving sarcopenia by providing food or health functional food in various formulations.

Although the preferred embodiments of the present invention have been described in detail above, the scope of the present invention is not limited thereto, and various modifications and improvements of those skilled in the art using the basic concept of the present invention defined in the following claims are also made according to the present invention. falls within the scope of the rights of

Claims (9)

containing brewer's yeast powder
A composition for preventing or improving sarcopenia. According to claim 1,
Further containing soybean leaf extract
A composition for preventing or improving sarcopenia. According to claim 2,
Selected from the group consisting of peppermint extract, apple mint extract, sage extract, lavender extract, bay extract, thyme extract, oregano extract, borage extract, chamomile extract, lemon balm extract, basil extract, rosemary extract, chrysanthemum extract, and mixtures thereof including any
A composition for preventing or improving sarcopenia. According to claim 2,
The composition has anti-Myostatin activity
A composition for preventing or improving sarcopenia. According to claim 2,
The extract is extracted using an extraction solvent selected from the group consisting of water, alcohol having 1 to 6 carbon atoms, and mixtures thereof.
A composition for preventing or improving sarcopenia. According to claim 2,
The sarcopenia includes muscular dystrophy, myasthenia gravis, muscular dystrophy, myasthenia, hypotonia, muscle weakness, muscular dystrophy, amyotrophic lateral sclerosis or myasthenia gravis.
A composition for preventing or improving sarcopenia. A food containing the composition for preventing or improving sarcopenia according to any one of claims 1 to 6. A health functional food comprising the composition for preventing or improving sarcopenia according to any one of claims 1 to 6. Peppermint extract, apple mint extract, sage extract, lavender extract, bay extract, thyme extract, oregano extract, borage extract, chamomile extract, lemon balm extract, basil extract, bean leaf extract, rosemary extract, chrysanthemum extract, and mixtures thereof A drying step of drying any one plant selected from the group;
Powdering step of pulverizing the dried plants according to the drying step;
A plant extract preparation step of preparing an extract by adding an extraction solvent selected from the group consisting of water, alcohol having 1 to 6 carbon atoms, and mixtures thereof to the plant subjected to the powdering step; and
Comprising a brewer's yeast mixing step of mixing brewer's yeast with the plant extract
A method for preparing a composition for preventing or improving sarcopenia.

Images